Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Cash Flows (Unaudited)

v3.22.4
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities    
Loss for the period $ (8,050) $ (11,859)
Adjustments to reconcile net loss to net cash used in operating activities    
Amortization of clinical trial deposit 1,075  
Depreciation of property and equipment 30 30
Change in fair value of milestone liability (83) (4)
Warrants issued for services   35
Stock option expense 954 1,641
Changes in operating assets and liabilities    
Prepaid expenses, deposits and other (48) (678)
Clinical trial deposit (1,700)  
Accounts payable and accrued liabilities (535) 676
Related party payables (173) (18)
Net cash used in operating activities (8,530) (10,177)
Cash flows from investing activities    
Purchase of equipment (232)  
Net cash used in investing activities (232)  
Cash flows from financing activities    
Net proceeds from the issuance of shares and warrants 1,860 13,634
Warrants exercised for cash   74
Series A Preferred cash dividend (4) (4)
Net cash provided by financing activities 1,856 13,704
(Decrease) increase in cash and cash equivalents (6,906) 3,527
Cash and cash equivalents – beginning of period 11,780 10,537
Cash and cash equivalents – end of period $ 4,874 $ 14,064